Return to the tumor core battlefield, can GlaxoSmithKline plc Sponsored ADR (GSK.US) narrow the gap with Astrazeneca PLC Sponsored ADR through Nuvalent?

GlaxoSmithKline plc Sponsored ADR (GSK.US) made a record-breaking $10.6 billion acquisition of the American biotechnology company Nuvalent, in a move to accelerate the rebuilding of its cancer drug business to compete with larger rivals like Astrazeneca PLC Sponsored ADR (AZN.US) and Roche (RHHBY.US). This acquisition, codenamed "Nashville," is the largest deal to date for GlaxoSmithKline plc Sponsored ADR, including two lung cancer treatments expected to be approved in the U.S. this year. The deal is expected to be completed in the third quarter. The acquisition aligns with the strategic plan of newly appointed CEO Luke Miels, who plans to expand GlaxoSmithKline plc Sponsored ADR's presence in the oncology field. Ten years ago, GlaxoSmithKline plc Sponsored ADR exited the field through a more than $16 billion asset swap deal with Novartis AG Sponsored ADR (NVS.US). This deal also helps hedge against the impact of the patent cliff at the end of the decade. Sales of the HIV drug dolutegravir are expected to be affected by then. Analysts estimate GlaxoSmithKline plc Sponsored ADR's total drug sales for this year to be around 34 billion ($45.3 billion). The acquisition of Nuvalent follows a series of smaller oncology investments by GlaxoSmithKline plc Sponsored ADR, including the $5.1 billion acquisition of Tesaro in 2018, the nearly $2 billion acquisition of Sierra Oncology, and several billion dollars in licensing deals. "Our strategy has always been to add up, step by step," Miels told reporters after announcing the acquisition of Nuvalent on Tuesday. "A very big brick" James Eugene, an analyst at GlaxoSmithKline plc Sponsored ADR shareholder Verso Investment Management, described Nuvalent as "a very big brick" in the overall rebuilding process of GlaxoSmithKline plc Sponsored ADR. Other investors share a similar view. Elena Meng, portfolio manager at Gabelli Funds, a holder of GlaxoSmithKline plc Sponsored ADR ADRs, noted, "The scale of this deal is clearly larger than any in the history of GlaxoSmithKline plc Sponsored ADR." She added that the company's oncology strategy has been established, with the new element being the size of the investment. A person close to the deal revealed that Nuvalent had faced multiple bidders, partly explaining why the acquisition premium was 40% higher than the biotech company's closing price before the announcement. This source stated that the company had been in the sights of large pharma companies for at least 18 months, as one of the few with late-stage oncology assets nearing approval. Correcting strategic mistakes Some investors see the return to oncology as correcting a strategic mistake from the era of former CEO Andrew Witty when GlaxoSmithKline plc Sponsored ADR exited the field and focused on vaccines, respiratory drugs, and consumer health. This shift actually began under Miels' predecessor Emma Walmsley, who took over in 2017. Markus Manns, portfolio manager at Union Investment, a shareholder of GlaxoSmithKline plc Sponsored ADR, stated, "Selling the oncology business line in 2015 was undoubtedly a mistake." He added that the acquisition of Nuvalent brings products with reduced risk, with peak sales potential reaching $3 to 4 billion, helping offset the impact of HIV drug patent expirations and assisting GlaxoSmithKline plc Sponsored ADR in achieving its sales target of 40 billion by 2031. GlaxoSmithKline plc Sponsored ADR does not intend to directly compete with Merck & Co., Inc. (MRK.US), Astrazeneca PLC Sponsored ADR, or Roche in all areas of oncology, but sees it as a potential growth area. The acquisition of Nuvalent will add two late-stage drugs to GlaxoSmithKline plc Sponsored ADR's portfolio. GlaxoSmithKline plc Sponsored ADR's Chief Scientific Officer Tony Wood stated before the deal, "A specialist pharma company without an oncology sector would be significantly discounted in terms of business integrity." Challenges and market reactions GlaxoSmithKline plc Sponsored ADR now needs to prove that these two lung cancer treatments targeting ROS1-positive and ALK-positive mutations can compete with existing products from Pfizer Inc. (PFE.US) and Roche and confirm their tolerance advantage. Analysts at Barclays believe the acquisition is justified but caution that these two assets may not have the potential of a "blockbuster." GlaxoSmithKline plc Sponsored ADR expects that if these therapies can reduce side effects compared to existing drugs and allow young, active patients to continue treatment for years, then a smaller patient population could turn into a significant market opportunity. Ketan Patel, fund manager at the London-based family investment office Whitefriars, stated that while the acquisition of Nuvalent is an important step, GlaxoSmithKline plc Sponsored ADR still needs to complete more deals to truly compete in the oncology field. "GlaxoSmithKline plc Sponsored ADR is playing catch-up," he mentioned the leading positions of Roche and Merck & Co., Inc. in the field, "I think they are still far behind and it's unlikely they will catch up with those names, so they may need to pay a higher price to compete in the same arena."